We are live on ! Find out more
GWPH

GW Pharmaceuticals Plc American Depositary Shares
GWPH

Delisted

GWPH was delisted on the 4th of May, 2021.

316 hedge funds and large institutions have $2.86B invested in GW Pharmaceuticals Plc American Depositary Shares in 2019 Q3 according to their latest regulatory filings, with 50 funds opening new positions, 103 increasing their positions, 82 reducing their positions, and 51 closing their positions.

New
Increased
Maintained
Reduced
Closed

61% more call options, than puts

Call options by funds: $256M | Put options by funds: $159M

26% more repeat investments, than reductions

Existing positions increased: 103 | Existing positions reduced: 82

1% less funds holding

Funds holding: 318316 (-2)

2% less first-time investments, than exits

New positions opened: 50 | Existing positions closed: 51

20% less funds holding in top 10

Funds holding in top 10: 54 (-1)

34% less capital invested

Capital invested by funds: $4.35B → $2.86B (-$1.49B)

Holders
316
Holders Change
-2
Holders Change %
-0.63%
% of All Funds
6.93%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.09%
New
50
Increased
103
Reduced
82
Closed
51
Calls
$256M
Puts
$159M
Net Calls
+$97.1M
Net Calls Change
+$143M
Name Holding Trade Value Shares
Change
Change in
Stake
EFSCE
226
Enterprise Financial Services Corp (EFSC)
Missouri
$43K
Walleye Trading
227
Walleye Trading
New York
$39K +$51.5K +339 New
FCA
228
FinTrust Capital Advisors
South Carolina
$38K
LC
229
Lindbrook Capital
California
$37K
PCG
230
Private Capital Group
Connecticut
$37K +$8.35K +55 +20%
AIC
231
Ameritas Investment Company
Nebraska
$37K +$45.7K +301 New
PNC Financial Services Group
232
PNC Financial Services Group
Pennsylvania
$36K -$15.2K -100 -24%
HNB
233
Huntington National Bank
Ohio
$36K
FANJ
234
Financial Architects (New Jersey)
New Jersey
$35K
Fifth Third Bancorp
235
Fifth Third Bancorp
Ohio
$31K -$1.37K -9 -3%
EWM
236
Edge Wealth Management
New York
$31K
VFA
237
Valeo Financial Advisors
Indiana
$30K +$30.4K +200 +323%
RWA
238
Ropes Wealth Advisors
Massachusetts
$29K +$6.07K +40 +19%
S
239
SignatureFD
Georgia
$27K +$23.4K +154 +193%
LF
240
Lee Financial
Texas
$25K
CFN
241
Cordasco Financial Network
Florida
$23K
CFGS
242
Concourse Financial Group Securities
Alabama
$22K -$3.19K -21 -10%
Daiwa Securities Group
243
Daiwa Securities Group
Japan
$22K +$607 +4 +2%
CTC
244
Central Trust Company
Missouri
$21K
LWA
245
Lenox Wealth Advisors
New York
$21K
LFG
246
LifePlan Financial Group
Ohio
$21K
TFS
247
TrustCore Financial Services
Tennessee
$21K +$12.6K +83 +83%
PFO
248
Pathstone Family Office
New Jersey
$20K
HI
249
Hudock Inc
Pennsylvania
$20K +$15.8K +104 +149%
PWMG
250
Prestige Wealth Management Group
New Jersey
$19K

GWPH Hedge Fund Activity: Q3 2019 in Review

316 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in GW Pharmaceuticals Plc American Depositary Shares (GWPH) for Q3 2019, worth a combined $2.86B — down 34% from $4.35B a quarter earlier.

Sellers outnumbered buyers: 51 funds closed out of GWPH and 50 opened new positions — a net loss of 1 holder — while 82 trimmed existing stakes and 103 added.

The largest buyer was Millennium Management, opening a new position worth an estimated $130M. The largest seller was Capital World Investors, cutting an estimated $268M.

  • 316 institutional investors held GW Pharmaceuticals Plc American Depositary Shares (GWPH) as of Q3 2019, down from 318 in Q2 2019.
  • Funds reported $2.86B of GW Pharmaceuticals Plc American Depositary Shares stock for Q3 2019, down 34% quarter-over-quarter.
  • 50 funds opened new GW Pharmaceuticals Plc American Depositary Shares positions in Q3 2019 and 51 closed out, a net change of -1 holder.
  • The largest GW Pharmaceuticals Plc American Depositary Shares buyer in Q3 2019 was Millennium Management, an estimated $130M added.
  • The largest GW Pharmaceuticals Plc American Depositary Shares seller in Q3 2019 was Capital World Investors, an estimated $268M sold.

Based on aggregated 13F filings for Q3 2019.